Ambu A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0060946788
DKK
87.25
-108.67 (-55.47%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ambu A/S stock-summary
stock-summary
Ambu A/S
Pharmaceuticals & Biotechnology
Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products from resuscitators, face masks and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
Company Coordinates stock-summary
Company Details
Baltorpbakken 13 , BALLERUP None : 2750
stock-summary
Tel: 45 72 25200045 26 208047
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lars Rasmussen
Chairman of the Board
Mr. Mikael Worning
Independent Vice Chairman of the Board
Mr. Jakob Boennelykke Kristensen
Director, Employee Representative
Mr. Jakob Koch
Director, Employee Representative
Mr. Thomas Lykke Henriksen
Director, Employee Representative
Ms. Britt Meelby Jensen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,507 Million
(Quarterly Results - Jun 2025)
Net Profit:
123 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 20,302 Million ()

stock-summary
P/E

69.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.76%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

10.09%

stock-summary
Price to Book

3.36